Literature DB >> 11407595

The role of p53 in human cancer.

D Malkin1.   

Abstract

In the two decades since its original discovery, p53 has found a singularly prominent place in our understanding of human cancer. Although the biochemistry of p53 has been worked out in some detail, our knowledge of the biologic consequences of p53 dysfunction is still quite rudimentary. Over the next several years, it will be important to determine how best to harness the complex properties of p53's ability to induce cellular growth arrest and cell death to generate novel, effective approaches to cancer therapy. Furthermore, a clearer appreciation of the direct interaction of epigenetic factors with p53 will lead to development of strategies to inhibit tumour initiation and progression. The next decade promises to offer exciting opportunities to apply our vast knowledge of this intriguing tumor suppressor to clinical advantage.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11407595     DOI: 10.1023/a:1010636426860

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.130


  125 in total

1.  A model for p53-induced apoptosis.

Authors:  K Polyak; Y Xia; J L Zweier; K W Kinzler; B Vogelstein
Journal:  Nature       Date:  1997-09-18       Impact factor: 49.962

2.  Solution structure of the tetrameric minimum transforming domain of p53.

Authors:  W Lee; T S Harvey; Y Yin; P Yau; D Litchfield; C H Arrowsmith
Journal:  Nat Struct Biol       Date:  1994-12

3.  Cell cycle. p21 inhibits cyclin shock.

Authors:  J Pines
Journal:  Nature       Date:  1994-06-16       Impact factor: 49.962

4.  Abrogation of wild-type p53 mediated growth-inhibition by nuclear exclusion.

Authors:  U Knippschild; M Oren; W Deppert
Journal:  Oncogene       Date:  1996-04-18       Impact factor: 9.867

Review 5.  Li-Fraumeni syndrome--a molecular and clinical review.

Authors:  J M Varley; D G Evans; J M Birch
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

6.  Nuclear and nucleolar targeting sequences of c-erb-A, c-myb, N-myc, p53, HSP70, and HIV tat proteins.

Authors:  C V Dang; W M Lee
Journal:  J Biol Chem       Date:  1989-10-25       Impact factor: 5.157

7.  Rescue of embryonic lethality in Mdm2-deficient mice by absence of p53.

Authors:  S N Jones; A E Roe; L A Donehower; A Bradley
Journal:  Nature       Date:  1995-11-09       Impact factor: 49.962

8.  Retention of wild-type p53 in tumors from p53 heterozygous mice: reduction of p53 dosage can promote cancer formation.

Authors:  S Venkatachalam; Y P Shi; S N Jones; H Vogel; A Bradley; D Pinkel; L A Donehower
Journal:  EMBO J       Date:  1998-08-17       Impact factor: 11.598

9.  A second p53-related protein, p73L, with high homology to p73.

Authors:  M Senoo; N Seki; M Ohira; S Sugano; M Watanabe; S Inuzuka; T Okamoto; M Tachibana; T Tanaka; Y Shinkai; H Kato
Journal:  Biochem Biophys Res Commun       Date:  1998-07-30       Impact factor: 3.575

10.  Cancer phenotype correlates with constitutional TP53 genotype in families with the Li-Fraumeni syndrome.

Authors:  J M Birch; V Blair; A M Kelsey; D G Evans; M Harris; K J Tricker; J M Varley
Journal:  Oncogene       Date:  1998-09-03       Impact factor: 9.867

View more
  8 in total

Review 1.  Malignant glioma: neuropathology and neurobiology.

Authors:  Matthias Preusser; Christine Haberler; Johannes A Hainfellner
Journal:  Wien Med Wochenschr       Date:  2006-06

Review 2.  The molecular genetics of adrenocortical carcinoma.

Authors:  Ferdous M Barlaskar; Gary D Hammer
Journal:  Rev Endocr Metab Disord       Date:  2007-12       Impact factor: 6.514

Review 3.  Gene Therapy for Lung Cancer.

Authors:  Humberto Lara-Guerra; Jack A Roth
Journal:  Crit Rev Oncog       Date:  2016

4.  Neurotoxicity of platinum compounds: comparison of the effects of cisplatin and oxaliplatin on the human neuroblastoma cell line SH-SY5Y.

Authors:  Elisabetta Donzelli; Maria Carfì; Mariarosaria Miloso; Alberto Strada; Stefania Galbiati; Martine Bayssas; Genevieve Griffon-Etienne; Guido Cavaletti; Maria Grazia Petruccioli; Giovanni Tredici
Journal:  J Neurooncol       Date:  2004 Mar-Apr       Impact factor: 4.130

5.  Constitutional haploinsufficiency of tumor suppressor genes in mentally retarded patients with microdeletions in 17p13.1.

Authors:  A C V Krepischi-Santos; D Rajan; I K Temple; V Shrubb; J A Crolla; S Huang; S Beal; P A Otto; N P Carter; A M Vianna-Morgante; C Rosenberg
Journal:  Cytogenet Genome Res       Date:  2009-07-14       Impact factor: 1.636

6.  Mutation of p53 in recurrent hepatocellular carcinoma and its association with the expression of ZBP-89.

Authors:  George G Chen; Juanita L Merchant; Paul B S Lai; Rocky L K Ho; Xu Hu; Morihiro Okada; Sheng F Huang; Albert K K Chui; David J Law; Yong G Li; Wan Y Lau; Arthur K C Li
Journal:  Am J Pathol       Date:  2003-06       Impact factor: 4.307

7.  Genotyping of BRCA1, BRCA2, p53, CDKN2A, MLH1 and MSH2 genes in a male patient with secondary breast cancer.

Authors:  Ana Lina Vodusek; Srdjan Novakovic; Vida Stegel; Berta Jereb
Journal:  Radiol Oncol       Date:  2011-09-22       Impact factor: 2.991

8.  Duplex Detection of TP53 Arg72Pro and 16 bp Del/Ins Polymorphisms by a Simple Optimized PCR-RFLP Method.

Authors:  B Lajin; A Alachkar; Sakur A Alhaj
Journal:  N Am J Med Sci       Date:  2012-05
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.